Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early ER-positive/HER2-negative breast cancer
CTR20190128Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in breast cancer, sponsored by Merck & Co.. Started Sep 2019; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190128.